# Ivabradine to Prevent Anthracycline-induced Cardiotoxicity

Study · id `cardio:ct-nct04030546` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04030546](<https://clinicaltrials.gov/study/NCT04030546>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04030546

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 128 participants.

## Technical summary

Registry record NCT04030546. Randomized; single masking; primary purpose treatment. Start 2019-06-01 (actual); primary completion 2020-06-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 128 participants (planned count; ClinicalTrials.gov record NCT04030546, source copy `cardio:ctgov-nct04030546-2019-12-18`, retrieved 2026-10-26)
- Started: 2019-06-01 (actual) (ClinicalTrials.gov record NCT04030546, source copy `cardio:ctgov-nct04030546-2019-12-18`, retrieved 2026-10-26)
- Primary completion: 2020-06-01 (anticipated) (ClinicalTrials.gov record NCT04030546, source copy `cardio:ctgov-nct04030546-2019-12-18`, retrieved 2026-10-26)
- Completion: 2020-12-31 (anticipated) (ClinicalTrials.gov record NCT04030546, source copy `cardio:ctgov-nct04030546-2019-12-18`, retrieved 2026-10-26)
- Countries: Lithuania (ClinicalTrials.gov record NCT04030546, source copy `cardio:ctgov-nct04030546-2019-12-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04030546-2019-12-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: Ivabradine to Prevent Anthracycline-induced Cardiotoxicity
- Condition: Patients With Cancer
- Intervention (Drug): Ivabradine
- Lead sponsor: Vilnius University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)

## Provenance

Content hash: e5f29e71eb8969ad1817f7088376b2a0920473fad98d099364a15dc715be11c9
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
